A number of in vitro and in vivo studies (for review see Kaye & Merry, 1985) have shown that resistance to adriamycin (doxorubicin; ADR) can be circumvented by the calcium antagonist verapamil (VPM). This effect has been noted both in animal and in human tumour lines and a clinical trial investigating the value of this approach in human small cell lung cancer is underway (Milroy et al., 1987) . However, concern has been expressed because the maximum clinically achievable VPM levels in plasma (1-2 pM) are somewhat lower than those which are consistently active in vitro in reversing ADR resistance (generally 6 yM). A major metabolite of VPM is the N-demethylated derivative norverapamil (NVPM; Figure 1 ) and following oral dosing NVPM is present in plasma in equimolar concentrations to VPM within 2-3 h (Hamann et al., 1984a) . If this metabolite were active in the context of overcoming drug resistance the effective concentration of modulating agent in vivo would be increased and the clinical potential of verapamil might be improved. In this short report we present data on the ability of both VPM and NVPM to enhance sensitivity to ADR in a murine tumour cell line.
MOG-XMT1 is a murine cell line derived from a tumour arising at the site of implantation of a human small cell lung cancer as a xenograft in an MFI-nu/Ola nude mouse. The cell line was shown to be of murine origin by LDH isoenzyme analysis (Hay, 1986) and karyotype. The cell line was tumorigenic in immunocompetent mice giving rise to well vascularised anaplastic tumours in which the predominant cell type was epithelioid. The cells were grown as monolayer cultures in RPMI 1640 supplemented with 10% fetal calf serum and with a gas phase of 2% CO2 in air. Cell suspensions were prepared by trypsinisation and counted electronically using a Coulter ZB cell counter.
ADR was obtained from Farmitalia (Barnet, Herts, UK), VPM was obtained from Abbot Laboratories (Queensborough, Kent, UK) and NVPM was a gift from Knoll AG (Ludwigshafen, FR Germany). Stock solutions (2mg ml ADR in isotonic lactose; 2.5mg ml-I VPM or NVPM in saline) were stored as frozen aliquots in the dark until use (generally no longer than 3 weeks). 3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium (thiazolyl blue; MTT) was obtained from Sigma (Poole, Dorset, UK).
In vitro cytotoxicity assays were performed using either MTT reduction to the coloured formazan product (Carmichael et al., 1987) where M is the modulating agent (or combination of modulating agents) employed in that particular assay. Sensitisation ratios were calculated using cytotoxicity curves derived from two to six replicates of five drug concentrations within a single experiment and all experiments were repeated at least three times. Figure 2 shows the results of a typical MTT experiment. The general shape of the curves were similar in all experiments. In this case 6.6 gM VPM and 6.6 pM NVPM are seen to produce sensitisation ratios of 3 and the difference in absorbance at 56 nM ADR is significant in both cases (P <0.01; Student's t test). In replicate experiments a similar difference between the curves was observed and no significant toxicity with either modulating agent alone was noted. Table I summarises the results of our MTT experiments. The ID50 of ADR in the absence of VPM was 106+15 nM (mean + s.e.m., n = 13). The data show that the activity of VPM and NVPM in enhancing sensitivity to ADR is dosedependent. It can also be seen that NVPM is equally active to VPM and shows a similar dose-response relationship.
Furthermore at lower doses (0.6 and 2.0 gM) the combination of VPM and NVPM produced a greater effect on ADR sensitivity than either modulating agent alone with the difference being statistically significant (P < 0.05; Student's t test) at 2.0 pM. At 6.6 /IM, however, the addition of NVPM to VPM did not increase the sensitisation ratio; suggesting that the effect of either is maximal at this concentration. In a separate series of experiments 2.0 pM VPM + 0.6 gM NVPM (the peak plasma concentrations obtained in mice treated with the maximum tolerated dose of VPM i.p.; Merry et al., 1988) produced a sensitisation ratio of 2.4+0.5 (mean+s.e.m., n=3).
A similar dose-response curve (data not shown) for the effect of VPM on ADR sensitivity in MOG-XMT1 was also obtained using a previously described (Merry et al., 1984) cytotoxicity assay with 3H-leucine incorporation as end-point. Figure 3 shows the results of typical cloning experiments.
In this case 6.6 yM VPM and 6.6 gM NVPM are seen to produce sensitisation ratios of 22 6.6 pM NVPM at 43 nM ADR. The ID50 of ADR in the absence of VPM was 40.3 + 5.5 nM (mean +s.e.m., n = 13) and plating efficiency of untreated controls was 17.5 + 2.9% (mean + s.e.m., n = 11). Colony formation in the presence of 6.6pM VPM alone or 6.6 pM NVPM alone was 83.9 + 4.4% (mean + s.e.m., n = 5) and 107.6 + 3.0% (mean + s.e.m., n = 4) respectively relative to untreated controls. Thus the ability of 6.6 pM VPM or NVPM to increase sensitivity to ADR in this cell line has been confirmed in monolayer cloning experiments although the relative efficacy of VPM and NVPM in enhancing ADR sensitivity is more difficult to assess in this assay than in the MTT experiments. While the sensitisation ratio obtained with VPM was almost 4-fold that obtained with NVPM, 6.6 gM VPM caused a 16% reduction in colony formation in the absence of ADR. This contrasts with the absence of toxicity with either VPM or NVPM in the MTT experiments or with NVPM in the cloning experiments. The VPM toxicity seen in the cloning experiments could be the result of the longer period of exposure.
The plasma pharmacokinetics of VPM have been well documented. It has been shown that plasma concentrations of up to 6pM VPM may be achieved by intravenous infusion (Ozols et al., 1987) , but these are associated with significant cardiovascular toxicity. Clinical trials (Benson et al., 1985; Cantwell et al., 1985) have, however, shown that steady state concentrations of VPM in plasma of 0.5-1 /pM can be maintained with limited toxicity. VPM concentrations that have been used to effectively circumvent ADR resistance in vitro (generally 6.6uM) are higher than clinically achievable plasma levels (1-2,pM) and these disappointing results may have previously dissuaded researchers from pursuing this approach in the clinic.
Data from two sources, however, suggest that clinical studies should proceed. First, Slater et al., (1982) uu -reported that levels of 2-50 pg VPM g-1 tissue and 10-50pg NVPM g-tissue in lung, liver, kidney and heart from rats treated with 30mg kg-VPM i.p. These levels were maintained for at least 4 h (the duration of the experiment).
While it is acknowledged that the pharmacodynamics of exposure of cells to VPM and NVPM in this in vitro study may be dissimilar to those encountered in vivo, the concentration x time product of the 24h exposure to 0.6-6.6pM (0.3-3.2pgml-P) VPM or NVPM used in our MTT assay may approximate that found in normal rat tissues (see above). Furthermore, in the cloning experiments (in which cells were exposed to 6.6pM VPM or NVPM for 9-11 days) circumvention of ADR resistance was also seen. The demonstration that VPM and NVPM can circumvent ADR resistance using two different experimental protocols (with different end-points and conditions of drug exposure) reduces the likelihood that this phenomenon is an experimental artefact.
Previous studies from this department (Kerr et al., 1986; Merry et al., 1988) have also shown that the metabolite NVPM is present in approximately equal concentrations to VPM in the plasma of patients treated with oral VPM and is also present in significant amounts in the plasma of mice treated with VPM i.p. It is also important to note that, while NVPM may contribute to the ability of VPM to circumvent ADR resistance, the contribution of NVPM to the cardiovascular side-effects may be small. Naugebauer (1978) has reported that NVPM has only 20% of the coronary vasodilator activity of VPM in dogs. In this paper we have shown that NVPM has a similar activity to VPM in enhancing the sensitivity of a murine tumour cell line to ADR in vitro and that at pharmacologically relevant concentrations NVPM can increase enhancement of sensitivity to ADR caused by VPM. Plasma and tissue concentrations of VPM may thus represent only half the potential modulating activity and by ignoring the contribution of this metabolite the clinical potential of VPM in overcoming ADR resistance may have previously been significantly underestimated.
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